[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632225":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":36,"centralContacts":37,"locations":36,"responsibleParty":43,"collaborators":36,"id":47,"slug":36,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":36,"enrollmentInfo":56,"targetDuration":36,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":36,"overallStatus":69,"whyStopped":36,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":36},{"fullName":5,"class":6},"Isala","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CGM-guided glucose management","EXPERIMENTAL","Participants receive glucose monitoring using a continuous glucose monitoring (CGM) system (FreeStyle Libre 2). Glucose management during hospitalization is guided by CGM measurements and used for treatment decisions according to the hospital glucose management protocol.",[13],"Device: Continuous Glucose Monitoring",{"label":15,"type":16,"description":17,"interventionNames":18},"POCT-guided glucose management","ACTIVE_COMPARATOR","Participants receive standard glucose monitoring using intermittent point-of-care testing (POCT) with capillary finger-prick measurements. Glucose management during hospitalization follows the hospital glucose management protocol based on POCT values. A blinded continuous glucose monitoring sensor (FreeStyle Libre Pro iQ) is placed for data collection purposes only. CGM data are not available to the clinical team and are not used for treatment decisions.",[19],"Diagnostic Test: Point-of-Care Testing",[21,29],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Continuous Glucose Monitoring","Continuous glucose monitoring using the FreeStyle Libre systems (Abbott Diabetes Care) to measure interstitial glucose levels through a subcutaneous sensor that continuously records glucose concentrations during hospitalization.",[9],[27,28],"FreeStyle Libre 2","CGM",{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DIAGNOSTIC_TEST","Point-of-Care Testing","Intermittent glucose monitoring using point-of-care finger-prick capillary blood glucose measurements according to the hospital glucose management protocol.",[15],[35],"POCT",null,[38],{"name":39,"role":40,"phone":41,"phoneExt":36,"email":42},"Peter R van Dijk, MD PhD","CONTACT","+316 88 624 50 00","p.r.van.dijk@isala.nl",{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":36,"oldOrganization":36},"PRINCIPAL_INVESTIGATOR","Peter van Dijk","Principal Investigator, Internist-Endocrinologist","100632225",false,"NCT07510919","CGM in Acute Ischemic Stroke","Continuous Glucose Monitoring for Enhanced Management of Hyperglycemia in Persons With Type 2 Diabetes Undergoing Endovascular Therapy for Acute Ischemic Stroke: a Randomized Controlled Trial.","SENSTROKE","Inclusion Criteria:\n\n* Age ≥18 years\n* Acute ischemic stroke treated with endovascular therapy (EVT)\n* Type 2 diabetes mellitus, defined as one of the following:\n* documented diagnosis of type 2 diabetes mellitus\n* use of glucose-lowering medication\n* admission plasma glucose ≥11.1 mmol\u002FL\n* HbA1c ≥48 mmol\u002Fmol (≥6.5%)\n\nExclusion Criteria:\n\n* Current pregnancy\n* Extensive skin infections or dermatological conditions at the intended sensor site\n* Medical situations known to interfere with CGM accuracy, including:\n* Hypotension defined as a systolic blood pressure \\\u003C100 mmHg at 30 and 60 minutes after admission\n* Dialysis treatment\n* Estimated glomerular filtration rate (eGFR) \\\u003C15 mL\u002Fmin\u002F1.73 m²\n* Use of medications known to interfere with CGM accuracy, including:\n* Acetaminophen \\>4 g\u002Fday\n* Dopamine\n* High-dose vitamin C (ascorbic acid)\n* Hydroxyurea \u002F hydroxycarbamide\n* Clinically relevant pancreatic disease\n* Systemic glucocorticoid therapy with a prednisone-equivalent dose \\>5 mg\u002Fday\n* Expected admission to an intensive care unit (ICU)","ALL","18 Years",{"count":57,"type":58},82,"ESTIMATED","INTERVENTIONAL",[61],"NA","The goal of this randomized clinical trial is to evaluate whether continuous glucose monitoring (CGM) can be used to guide glucose management in patients with type 2 diabetes who are admitted with an acute ischemic stroke and undergo endovascular therapy. Hyperglycemia frequently occurs during hospitalization in stroke and is associated with worse neurological and clinical outcomes. In current clinical practice, glucose levels are monitored using intermittent point-of-care testing (POCT) with finger-prick measurements, which may miss clinically relevant glucose fluctuations. CGM provides continuous glucose measurements and may allow earlier detection of hyperglycemia and more timely glucose management.\n\nThis study is designed as a non-inferiority randomized controlled trial comparing CGM-guided glucose management with standard POCT-guided glucose management. The primary objective is to determine whether CGM-guided glucose management is non-inferior to POCT-guided management in terms of percentage time spent in hyperglycemia (glucose \\>10 mmol\u002FL) during the first 72 hours of hospitalization.\n\nResearchers will compare CGM-guided glucose management to POCT-guided glucose management to evaluate whether CGM can be used as an alternative strategy to guide glucose control in hospitalized stroke patients.\n\nParticipants will:\n\n* Be randomly assigned to either CGM-guided glucose management or standard POCT-guided glucose management\n* Have their glucose levels continuously monitored (blinded in the POCT-guided group) during hospitalization\n* Receive glucose management according to the assigned monitoring strategy, based on the hospital insulin protocol",[64,65,66,67,68],"Acute Ischemic Stroke","Diabetes (DM)","Diabetes Type 2","Hyperglycemia","Stroke","NOT_YET_RECRUITING","2026-03-31",{"date":72,"type":73},"2026-04-06","ACTUAL",{"date":75,"type":58},"2026-04",{"date":77,"type":58},"2028-08",{"name":5,"class":6}]